Literature DB >> 11840505

Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population.

Sylvia Bort Martí1, Sven Cichon, Peter Propping, Markus Nöthen.   

Abstract

In the present study, we sought to identify genetic variation in the metabotropic glutamate receptor 3 (GRM3) gene, which has been mapped to chromosome 7q21.1-q21.2 [Scherer et al., 1996] and might contribute to genetic predisposition to schizophrenia and/or bipolar affective disorder. Using single-strand conformation analysis (SSCA), we screened the complete coding sequence as well as adjacent splice sites of the GRM3 gene in a sample of 46 bipolar affective and 46 schizophrenic patients. We detected three sequence variants: a rare C/T substitution at nucleotide position +885 (T209T), a C/T substitution at nucleotide position +2130 (Y624Y), and a more common C/T substitution at nucleotide position +1131 (A291A). The occurrence of the +1131C/T variant was investigated in a sample of bipolar affective patients (n=283), schizophrenic patients (n=265), and ethnically matched controls (n=227). We observed a significant overrepresentation of the +1131T allele in schizophrenic patients when compared to controls (P=0.0022). This finding was followed up in an independent sample of schizophrenic patients (n=288) and controls (n=162) and 128 schizophrenic trios but could not be confirmed. It is therefore unlikely that this variant plays a major role in predisposing to schizophrenia and/or bipolar affective disorder at least in the German population. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11840505     DOI: 10.1002/ajmg.1624

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  28 in total

1.  Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia.

Authors:  Michael F Egan; Richard E Straub; Terry E Goldberg; Imtiaz Yakub; Joseph H Callicott; Ahmad R Hariri; Venkata S Mattay; Alessandro Bertolino; Thomas M Hyde; Cynthia Shannon-Weickert; Mayada Akil; Jeremy Crook; Radha Krishna Vakkalanka; Rishi Balkissoon; Richard A Gibbs; Joel E Kleinman; Daniel R Weinberger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-13       Impact factor: 11.205

Review 2.  Imaging genomics and response to treatment with antipsychotics in schizophrenia.

Authors:  Giuseppe Blasi; Alessandro Bertolino
Journal:  NeuroRx       Date:  2006-01

3.  Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia.

Authors:  Jeffrey R Bishop; Del D Miller; Vicki L Ellingrod; Timothy Holman
Journal:  Hum Psychopharmacol       Date:  2011-01       Impact factor: 1.672

Review 4.  Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists.

Authors:  John H Krystal; Sanjay J Mathew; D Cyril D'Souza; Amir Garakani; Handan Gunduz-Bruce; Dennis S Charney
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

Review 5.  The genetics of schizophrenia and bipolar disorder: dissecting psychosis.

Authors:  N Craddock; M C O'Donovan; M J Owen
Journal:  J Med Genet       Date:  2005-03       Impact factor: 6.318

6.  Metabotropic glutamate receptor 2 and 3 gene expression in the human prefrontal cortex and mesencephalon in schizophrenia.

Authors:  Subroto Ghose; Jeremy M Crook; Cynthia L Bartus; Thomas G Sherman; Mary M Herman; Thomas M Hyde; Joel E Kleinman; Mayada Akil
Journal:  Int J Neurosci       Date:  2008-11       Impact factor: 2.292

Review 7.  Imaging genetics of structural brain connectivity and neural integrity markers.

Authors:  Stefano Marenco; Eugenia Radulescu
Journal:  Neuroimage       Date:  2009-11-22       Impact factor: 6.556

Review 8.  Group II metabotropic glutamate receptors and schizophrenia.

Authors:  José L Moreno; Stuart C Sealfon; Javier González-Maeso
Journal:  Cell Mol Life Sci       Date:  2009-08-26       Impact factor: 9.261

Review 9.  The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia.

Authors:  Joseph T Coyle; Guochuan Tsai
Journal:  Psychopharmacology (Berl)       Date:  2003-11-25       Impact factor: 4.530

Review 10.  The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.

Authors:  Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Neuroscientist       Date:  2009-05-26       Impact factor: 7.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.